Please login to read the full article.
Scrip Regulatory Affairs
EMA reports high percentage of late paediatric investigation plans
10 May 2011
Vibha Sharma
Please login to read the full article.
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- EMA Q&As elaborate on paediatric use marketing authorisations and PIPs
- US lawmakers ask regulators to address underreporting of clinical trial data
- European court ruling means firms could face greater paediatric studies obligation beyond intended indication
- MEPs want list of drugs subject to extra monitoring to be more selective
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
Other Informa Analysis
EDITORIALS
Regulatory Affairs Pharma Editorials
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Regulatory Affairs Pharma Comment
Other Informa Comments
